N
Naifa L. Busaidy
Researcher at University of Texas MD Anderson Cancer Center
Publications - 161
Citations - 6158
Naifa L. Busaidy is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Thyroid cancer & Cancer. The author has an hindex of 37, co-authored 136 publications receiving 4522 citations. Previous affiliations of Naifa L. Busaidy include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators
Montserrat Ayala-Ramirez,Lei Feng,Marcella M. Johnson,Shamim Ejaz,Mouhammed Amir Habra,Thereasa A. Rich,Naifa L. Busaidy,Gilbert J. Cote,Nancy D. Perrier,Alexandria T. Phan,Shreyaskumar Patel,Steven G. Waguespack,Camilo Jimenez +12 more
TL;DR: The size and location of the primary tumor were significant clinical risk factors for metastasis and decreased overall survival duration and delineate the follow-up and treatment for these tumors.
Journal ArticleDOI
Selective RET kinase inhibition for patients with RET-altered cancers
Vivek Subbiah,Vamsidhar Velcheti,Brian B. Tuch,Kevin Ebata,Naifa L. Busaidy,Maria E. Cabanillas,Lori J. Wirth,S. Stock,Steven J. Smith,V. Lauriault,S. Corsi-Travali,Dahlia Henry,Mark E. Burkard,R. Hamor,Karyn Bouhana,Shannon L. Winski,R. D. Wallace,D. Hartley,S. Rhodes,M.G. Muni Reddy,Barbara J. Brandhuber,Steve Andrews,Stephen M. Rothenberg,A. Drilon +23 more
TL;DR: These results provide proof-of-concept of the clinical actionability of RET alterations, and identify selective RET inhibition by LOXO-292 as a promising treatment in heavily pretreated, multikinase inhibitor-experienced patients with diverse RET-altered tumors.
Journal ArticleDOI
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
Robert I. Haddad,Christian Nasr,Lindsay Bischoff,Naifa L. Busaidy,David R. Byrd,Glenda G. Callender,Paxton V. Dickson,Quan-Yang Duh,Hormoz Ehya,Whitney S. Goldner,Megan R. Haymart,Carl K. Hoh,Jason P. Hunt,Andrei Iagaru,Fouad Kandeel,Peter Kopp,Dominick Lamonica,Bryan McIver,Christopher D. Raeburn,John A. Ridge,Matthew D. Ringel,Randall P. Scheri,Jatin P. Shah,Rebecca S. Sippel,Robert C. Smallridge,Cord Sturgeon,Thomas N. Wang,Lori J. Wirth,Richard J. Wong,Alyse Johnson-Chilla,Karin G. Hoffmann,Lisa A. Gurski +31 more
TL;DR: The panel discussion behind recent updates to the NCCN Guidelines Insights summarized the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinomas.
Journal ArticleDOI
Parathyroid carcinoma: A 22-year experience
Naifa L. Busaidy,Camilo Jimenez,Mouhammed Amir Habra,Pamela N. Schultz,Adel K. El-Naggar,Gary L. Clayman,Joshua A. Asper,Eduardo M. Diaz,Douglas B. Evans,Robert F. Gagel,Adam S. Garden,Ana O. Hoff,Jeffrey E. Lee,William H. Morrison,David I. Rosenthal,Steven I. Sherman,Erich M. Sturgis,Steven G. Waguespack,Randal S. Weber,Kelly L. Wirfel,Rena Vassilopoulou-Sellin +20 more
TL;DR: Because parathyroid carcinoma is rare, clear consensus is not available regarding the optimal management of patients with this condition, and treatment strategies generally derive from clinical and anecdotal experiences.
Journal ArticleDOI
Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center
Montserrat Ayala-Ramirez,Sina Jasim,Lei Feng,Shamim Ejaz,Ferhat Deniz,Naifa L. Busaidy,Steven G. Waguespack,Aung Naing,Kanishka Sircar,Christopher G. Wood,Lance C. Pagliaro,Camilo Jimenez,Rena Vassilopoulou-Sellin,Mouhammed Amir Habra +13 more
TL;DR: The clinical features and outcomes for a large series of ACC patients seen at The University of Texas MD Anderson Cancer Center from 1998 through 2011 remain poor, and prognosis remains poor with the use of currently available treatments.